Reviewer’s report

Title: Thymostimulin in advanced hepatocellular carcinoma: a phase II trial

Version: 1 Date: 27 October 2007

Reviewer: Yo-ichi Yamashita

Reviewer’s report:

General
This paper is worth publishing, because this phase II study of thymostimulin in advanced HCC should be important for the constructing new treatment for HCC.

-------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

1) As authors mentioned, this paper has few new informations in phase II study of thymostimulin in advanced HCC. Therefore, the authors should mention about more details about the serection criteria for best responce for thymostimulin in "Abstract" and "Results" sections.

2) The authors should mention about more details about the 2 CR cases (CT and clinical course) and the clinical course of long survivor over 2 years.

3) I think that Table 4 was not important, therefore should be omitted.

-------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.